158 related articles for article (PubMed ID: 3987922)
1. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974.
Resseguie LJ; Hick JF; Bruen JA; Noller KL; O'Fallon WM; Kurland LT
Fertil Steril; 1985 Apr; 43(4):514-9. PubMed ID: 3987922
[TBL] [Abstract][Full Text] [Related]
2. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.
Northen AT; Norman GS; Anderson K; Moseley L; Divito M; Cotroneo M; Swain M; Bousleiman S; Johnson F; Dorman K; Milluzzi C; Tillinghast JA; Kerr M; Mallett G; Thom E; Pagliaro S; Anderson GD;
Obstet Gynecol; 2007 Oct; 110(4):865-72. PubMed ID: 17906021
[TBL] [Abstract][Full Text] [Related]
3. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy.
Waters TP; Schultz BAH; Mercer BM; Catalano PM
Obstet Gynecol; 2009 Jul; 114(1):45-49. PubMed ID: 19546757
[TBL] [Abstract][Full Text] [Related]
4. Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.
Romero R; Stanczyk FZ
Am J Obstet Gynecol; 2013 Jun; 208(6):421-6. PubMed ID: 23643669
[No Abstract] [Full Text] [Related]
5. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
6. Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy.
Tsur A; Leonard SA; Kan P; Datoc IA; Girsen AI; Shaw GM; Stevenson DK; El-Sayed YY; Druzin ML; Blumenfeld YJ
Am J Perinatol; 2023 Aug; 40(11):1158-1162. PubMed ID: 37100422
[TBL] [Abstract][Full Text] [Related]
7. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
O'Brien JM
Am J Perinatol; 2012 Oct; 29(9):665-72. PubMed ID: 22773279
[TBL] [Abstract][Full Text] [Related]
8. Genital and nongenital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse.
Carbone JP; Brent RL
Am J Obstet Gynecol; 1993 Nov; 169(5):1292-8. PubMed ID: 8238197
[TBL] [Abstract][Full Text] [Related]
9. Transplacental carcinogenesis (adrenocortical carcinoma) associated with hydroxyprogesterone hexanoate.
Mann JR; Cameron AH; Gornall P; Rayner PH; Shah KJ
Lancet; 1983 Sep; 2(8349):580. PubMed ID: 6136738
[No Abstract] [Full Text] [Related]
10. [Can synthetic progestogenic steroids during early pregnancy cause hypospadias in the male fetus?].
Larsson KS; Lindsten J; Ritzén M; Tillinger KG
Lakartidningen; 1971 May; 68(22):2565-6. PubMed ID: 5581395
[No Abstract] [Full Text] [Related]
11. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
12. The risk of fetal anomalies as a result of progesterone therapy during pregnancy.
Check JH; Rankin A; Teichman M
Fertil Steril; 1986 Apr; 45(4):575-7. PubMed ID: 3956772
[TBL] [Abstract][Full Text] [Related]
13. Iatrogenic autoimmune progesterone dermatitis caused by 17alpha-hydroxyprogesterone caproate for preterm labor prevention.
Bandino JP; Thoppil J; Kennedy JS; Hivnor CM
Cutis; 2011 Nov; 88(5):241-3. PubMed ID: 22272488
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy.
Varma TR; Morsman J
Int J Gynaecol Obstet; 1982 Feb; 20(1):13-7. PubMed ID: 6126401
[TBL] [Abstract][Full Text] [Related]
15. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
Hall NR
Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
[TBL] [Abstract][Full Text] [Related]
16. Vaginal adenosis in stillborns and neonates exposed to diethylstilbestrol and steroidal estrogens and progestins.
Johnson LD; Driscoll SG; Hertig AT; Cole PT; Nickerson RJ
Obstet Gynecol; 1979 Jun; 53(6):671-9. PubMed ID: 450333
[TBL] [Abstract][Full Text] [Related]
17. In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.
Murphy CC; Cirillo PM; Krigbaum NY; Cohn BA
Am J Obstet Gynecol; 2022 Jan; 226(1):132.e1-132.e14. PubMed ID: 34767803
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the teratogenic potential of delalutin (17 alpha-hydroxyprogesterone caproate) in mice.
Seegmiller RE; Nelson GW; Johnson CK
Teratology; 1983 Oct; 28(2):201-8. PubMed ID: 6648824
[TBL] [Abstract][Full Text] [Related]
19. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ
Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
